Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) will host an investor presentation on Oct. 21, 2026, at 9 a.m. EDT to highlight its clinical development programs for depression and anxiety. The event will focus on HLP003, the company’s proprietary novel serotonergic agonist (NSA) in Phase 3 development for the adjunctive treatment of major depressive disorder, and HLP004, its proprietary NSA in Phase 2 development for generalized anxiety disorder. The presentation will also include perspectives from key opinion leaders on the evolving depression and anxiety treatment landscape, followed by a question-and-answer session with Helus Pharma executives. A live webcast will be accessible through the company’s website, with a replay available after the event.
The announcement comes as Helus Pharma positions itself to address a large unmet need in mental health. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of major depressive disorder—a designation intended to expedite the development and review of drugs that may offer substantial improvement over existing therapies. HLP004 is in Phase 2 development for generalized anxiety disorder. Both compounds are part of Helus Pharma’s proprietary class of NSAs, which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company intends for these NSAs to provide durable improvements in mental health.
For investors and industry observers, the October presentation represents a critical look into Helus Pharma’s pipeline and strategic direction. With HLP003 in late-stage development and HLP004 advancing, the event could offer clarity on timelines, clinical data expectations, and potential market positioning. The inclusion of key opinion leaders may also shed light on how new serotonergic agonists could fit into treatment paradigms for depression and anxiety, conditions that affect millions worldwide. As a clinical-stage company, Helus Pharma’s progress will be closely watched by stakeholders assessing the risk and reward profile of its programs.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and operates in Canada, the United States, the United Kingdom, and Ireland. In addition to HLP003 and HLP004, the company maintains an extensive research portfolio of investigational NSAs. For company updates and to learn more, visit www.helus.com. The full press release can be viewed at https://ibn.fm/akaNj.
This news was disseminated through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. For more information, visit BioMedWire or review the full disclaimer at https://www.BioMedWire.com/Disclaimer.
